Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 2346585, 12 pages
http://dx.doi.org/10.1155/2016/2346585
Review Article

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine

1Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA
2Department of Otorhinolaryngology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA

Received 9 June 2016; Accepted 28 July 2016

Academic Editor: David C. Pauza

Copyright © 2016 Stephen Murata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Liang, S.-Y. Lin, F. C. Brunicardi, J. Goss, and K. Li, “DNA damage response pathways in tumor suppression and cancer treatment,” World Journal of Surgery, vol. 33, no. 4, pp. 661–666, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Helleday, E. Petermann, C. Lundin, B. Hodgson, and R. A. Sharma, “DNA repair pathways as targets for cancer therapy,” Nature Reviews Cancer, vol. 8, no. 3, pp. 193–204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Tian, Z. Gao, H. Li et al., “DNA damage response—a double-edged sword in cancer prevention and cancer therapy,” Cancer Letters, vol. 358, no. 1, pp. 8–16, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. N. McCabe, N. C. Turner, C. J. Lord et al., “Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition,” Cancer Research, vol. 66, no. 16, pp. 8109–8115, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. W. G. Kaelin Jr., “The concept of synthetic lethality in the context of anticancer therapy,” Nature Reviews Cancer, vol. 5, no. 9, pp. 689–698, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. S. D. Merajver, T. S. Frank, J. Xu et al., “Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer,” Clinical Cancer Research, vol. 1, no. 5, pp. 539–544, 1995. View at Google Scholar · View at Scopus
  7. K. Yoshida and Y. Miki, “Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage,” Cancer Science, vol. 95, no. 11, pp. 866–871, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Konishi, M. Mohseni, A. Tamaki et al., “Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 43, pp. 17773–17778, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Yata, J.-Y. Bleuyard, R. Nakato et al., “BRCA2 coordinates the activities of cell-cycle kinases to promote genome stability,” Cell Reports, vol. 7, no. 5, pp. 1547–1559, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. S. M. H. Sy, M. S. Y. Huen, and J. Chen, “PALB2 is an integral component of the BRCA complex required for homologous recombination repair,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 17, pp. 7155–7160, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. H. Houtgraaf, J. Versmissen, and W. J. van der Giessen, “A concise review of DNA damage checkpoints and repair in mammalian cells,” Cardiovascular Revascularization Medicine, vol. 7, no. 3, pp. 165–172, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Ashworth, “A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair,” Journal of Clinical Oncology, vol. 26, no. 22, pp. 3785–3790, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Underhill, M. Toulmonde, and H. Bonnefoi, “A review of PARP inhibitors: from bench to bedside,” Annals of Oncology, vol. 22, no. 2, pp. 268–279, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Lupo and L. Trusolino, “Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited,” Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, vol. 1846, no. 1, pp. 201–215, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Helleday, “The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings,” Molecular Oncology, vol. 5, no. 4, pp. 387–393, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Tangutoori, P. Baldwin, and S. Sridhar, “PARP inhibitors: a new era of targeted therapy,” Maturitas, vol. 81, no. 1, pp. 5–9, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Kummar, A. M. Oza, G. F. Fleming et al., “Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer,” Clinical Cancer Research, vol. 21, no. 7, pp. 1574–1582, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. J. F. Liu, P. A. Konstantinopoulos, and U. A. Matulonis, “PARP inhibitors in ovarian cancer: current status and future promise,” Gynecologic Oncology, vol. 133, no. 2, pp. 362–369, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. T. D. Penning, G.-D. Zhu, V. B. Gandhi et al., “Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer,” Journal of Medicinal Chemistry, vol. 52, no. 2, pp. 514–523, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. K. Sandhu, W. R. Schelman, G. Wilding et al., “The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial,” The Lancet Oncology, vol. 14, no. 9, pp. 882–892, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Ihnen, C. Z. Eulenburg, T. Kolarova et al., “Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer,” Molecular Cancer Therapeutics, vol. 12, no. 6, pp. 1002–1015, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. M. E. Moynahan, J. W. Chiu, B. H. Koller, and M. Jasint, “Brca1 controls homology-directed DNA repair,” Molecular Cell, vol. 4, no. 4, pp. 511–518, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. M. E. Moynahan, A. J. Pierce, and M. Jasin, “BRCA2 is required for homology-directed repair of chromosomal breaks,” Molecular Cell, vol. 7, no. 2, pp. 263–272, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Wooster, S. L. Neuhausen, J. Mangion et al., “Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13,” Science, vol. 265, no. 5181, pp. 2088–2090, 1994. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Kaufman, R. Shapira-Frommer, R. K. Schmutzler et al., “Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation,” Journal of Clinical Oncology, vol. 33, no. 3, pp. 244–250, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Tutt, M. Robson, J. E. Garber et al., “Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial,” The Lancet, vol. 376, no. 9737, pp. 235–244, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. K. A. Gelmon, M. Tischkowitz, H. Mackay et al., “Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study,” The Lancet Oncology, vol. 12, no. 9, pp. 852–861, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Buisson, A.-M. Dion-Côté, Y. Coulombe et al., “Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination,” Nature Structural and Molecular Biology, vol. 17, no. 10, pp. 1247–1254, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Rahman, S. Seal, D. Thompson et al., “PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene,” Nature Genetics, vol. 39, no. 2, pp. 165–167, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Obermeier, J. Sachsenweger, T. W. P. Friedl, H. Pospiech, R. Winqvist, and L. Wiesmüller, “Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients,” Oncogene, vol. 35, pp. 3796–3806, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. D. B. Zhen, K. G. Rabe, S. Gallinger et al., “BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study,” Genetics in Medicine, vol. 17, no. 7, pp. 569–577, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. W. Duan, L. Gao, B. Aguila, A. Kalvala, G. A. Otterson, and M. A. Villalona-Calero, “Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer,” Frontiers in Oncology, vol. 4, article 368, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Garcia-Higuera, T. Taniguchi, S. Ganesan et al., “Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway,” Molecular Cell, vol. 7, no. 2, pp. 249–262, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. X. Wang, P. R. Andreassen, and A. D. D'Andrea, “Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin,” Molecular and Cellular Biology, vol. 24, no. 13, pp. 5850–5862, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Willers, A. G. Taghian, C.-M. Luo, A. Treszezamsky, D. C. Sgroi, and S. N. Powell, “Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies,” Molecular Cancer Research, vol. 7, no. 8, pp. 1304–1309, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. M. R. G. Taylor, M. Špírek, K. R. Chaurasiya et al., “Rad51 paralogs remodel pre-synaptic Rad51 filaments to stimulate homologous recombination,” Cell, vol. 162, no. 2, pp. 271–286, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Scully, J. Chen, A. Plug et al., “Association of BRCA1 with Rad51 in mitotic and meiotic cells,” Cell, vol. 88, no. 2, pp. 265–275, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Pellegrini, D. S. Yu, T. Lo et al., “Insights into DNA recombination from the structure of a RAD51-BRCA2 complex,” Nature, vol. 420, no. 6913, pp. 287–293, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Raderschall, E. I. Golub, and T. Haaf, “Nuclear foci of mammalian recombination proteins are located at single- stranded DNA regions formed after DNA damage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 5, pp. 1921–1926, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Haaf, E. I. Golub, G. Reddy, C. M. Radding, and D. C. Ward, “Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 6, pp. 2298–2302, 1995. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Asakawa, H. Koizumi, A. Koike et al., “Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins,” Breast Cancer Research, vol. 12, no. 2, article R17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Graeser, A. McCarthy, C. J. Lord et al., “A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer,” Clinical Cancer Research, vol. 16, no. 24, pp. 6159–6168, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Min, S.-A. Im, Y.-K. Yoon et al., “RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib,” Molecular Cancer Therapeutics, vol. 12, no. 6, pp. 865–877, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Mukhopadhyay, A. Elattar, A. Cerbinskaite et al., “Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors,” Clinical Cancer Research, vol. 16, no. 8, pp. 2344–2351, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. S. V. Kozlov, A. J. Waardenberg, K. Engholm-Keller, J. W. Arthur, M. E. Graham, and M. F. Lavin, “Reactive Oxygen Species (ROS)-activated ATM-dependent phosphorylation of cytoplasmic substrates identified by large-scale phosphoproteomics screen,” Molecular & Cellular Proteomics, vol. 15, no. 3, pp. 1032–1047, 2016. View at Publisher · View at Google Scholar
  46. C. T. Williamson, H. Muzik, A. G. Turhan et al., “ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors,” Molecular Cancer Therapeutics, vol. 9, no. 2, pp. 347–357, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Kubota, C. T. Williamson, R. Ye et al., “Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines,” Cell Cycle, vol. 13, no. 13, pp. 2129–2137, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. P. Kalev, M. Simicek, I. Vazquez et al., “Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition,” Cancer Research, vol. 72, no. 24, pp. 6414–6424, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. R. S. Williams, J. S. Williams, and J. A. Tainer, “Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template,” Biochemistry and Cell Biology, vol. 85, no. 4, pp. 509–520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Koppensteiner, E. P. Samartzis, A. Noske et al., “Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro,” PLoS ONE, vol. 9, no. 6, Article ID e100041, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. S. A. Lajud, D. A. Nagda, T. Yamashita et al., “Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer,” Clinical Cancer Research, vol. 20, no. 24, pp. 6465–6478, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. T. J. Gaymes, A. M. Mohamedali, M. Patterson et al., “Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies,” Haematologica, vol. 98, no. 9, pp. 1397–1406, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. H. C. Reinhardt and B. Schumacher, “The p53 network: cellular and systemic DNA damage responses in aging and cancer,” Trends in Genetics, vol. 28, no. 3, pp. 128–136, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Holstege, H. M. Horlings, A. Velds et al., “BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations,” BMC Cancer, vol. 10, article 654, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. T. M. Severson, J. Peeters, I. Majewski et al., “BRCA1-like signature in triple negative breast cancer: molecular and clinical characterization reveals subgroups with therapeutic potential,” Molecular Oncology, vol. 9, no. 8, pp. 1528–1538, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. I. C. R. Ireno, R. S. T. Wiehe, A. I. U. Stahl et al., “Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53,” Carcinogenesis, vol. 35, no. 10, pp. 2273–2282, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Atsumi, Y. Minakawa, M. Ono et al., “ATM and SIRT6/SNF2H mediate transient H2AX stabilization when DSBs form by blocking HUWE1 to allow efficient γH2AX foci formation,” Cell Reports, vol. 13, no. 12, pp. 2728–2740, 2015. View at Publisher · View at Google Scholar
  58. L. J. Kuo and L.-X. Yang, “γ-H2AX-a novel biomaker for DNA double-strand breaks,” In Vivo, vol. 22, no. 3, pp. 305–309, 2008. View at Google Scholar · View at Scopus
  59. I. Faraoni, M. Compagnone, S. Lavorgna et al., “BRCA1, PARP1 and γH2AX in acute myeloid leukemia: role as biomarkers of response to the PARP inhibitor olaparib,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1852, no. 3, pp. 462–472, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Kummar, J. Ji, R. Morgan et al., “A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas,” Clinical Cancer Research, vol. 18, no. 6, pp. 1726–1734, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Kummar, A. Chen, J. Ji et al., “Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas,” Cancer Research, vol. 71, no. 17, pp. 5626–5634, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. V. Schreiber, F. Dantzer, J.-C. Amé, and G. De Murcia, “Poly(ADP-ribose): novel functions for an old molecule,” Nature Reviews Molecular Cell Biology, vol. 7, no. 7, pp. 517–528, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. C. E. Redon, A. J. Nakamura, Y.-W. Zhang et al., “Histone γH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers,” Clinical Cancer Research, vol. 16, no. 18, pp. 4532–4542, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Y. Kim, T. Zhang, and W. L. Kraus, “Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD+ into a nuclear signal,” Genes & Development, vol. 19, no. 17, pp. 1951–1967, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Nowsheen, J. A. Bonner, and E. S. Yang, “The poly(ADP-ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy,” Radiotherapy and Oncology, vol. 99, no. 3, pp. 331–338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Piao, H. Nakagawa, K. Ueda et al., “C12orf48, termed PARP-1 binding protein, enhances poly(ADP-ribose) polymerase-1 (PARP-1) activity and protects pancreatic cancer cells from DNA damage,” Genes Chromosomes and Cancer, vol. 50, no. 1, pp. 13–24, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. C. E. Ström, F. Johansson, M. Uhlén, C. A.-K. Szigyarto, K. Erixon, and T. Helleday, “Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate,” Nucleic Acids Research, vol. 39, no. 8, pp. 3166–3175, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Sultana, T. Abdel-Fatah, R. Abbotts et al., “Targeting XRCC1 deficiency in breast cancer for personalized therapy,” Cancer Research, vol. 73, no. 5, pp. 1621–1634, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. J. K. Horton, D. F. Stefanick, R. Prasad, N. R. Gassman, P. S. Kedar, and S. H. Wilson, “Base excision repair defects invoke hypersensitivity to PARP inhibition,” Molecular Cancer Research, vol. 12, no. 8, pp. 1128–1139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. C. J. Lord, S. McDonald, S. Swift, N. C. Turner, and A. Ashworth, “A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity,” DNA Repair, vol. 7, no. 12, pp. 2010–2019, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Dittmer, “The role of the transcription factor Ets1 in carcinoma,” Seminars in Cancer Biology, vol. 35, pp. 20–38, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Singh, J. Barrett, K. Sakata, R. G. Tozer, and G. Singh, “ETS proteins and MMPs: partners in invasion and metastasis,” Current Drug Targets, vol. 3, no. 5, pp. 359–367, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. J. C. Brenner and A. M. Chinnaiyan, “Translocations in epithelial cancers,” Biochimica et Biophysica Acta, vol. 1796, no. 2, pp. 201–215, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. K. M. Baker, G. Wei, A. E. Schaffner, and M. C. Ostrowski, “Ets-2 and components of mammalian SWI/SNF form a repressor complex that negatively regulates the BRCA1 promoter,” The Journal of Biological Chemistry, vol. 278, no. 20, pp. 17876–17884, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. V. Puzovic, I. Brcic, I. Ranogajec, and J. Jakic-Razumovic, “Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients,” Neoplasma, vol. 61, no. 4, pp. 439–446, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. A. J. Legrand, S. Choul-Li, C. Spriet et al., “The level of Ets-1 protein is regulated by poly(ADP-ribose) polymerase-1 (PARP-1) in cancer cells to prevent DNA damage,” PLoS ONE, vol. 8, no. 2, Article ID e55883, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. L. Liu, W. Zhou, C.-T. Cheng et al., “TGFβ Induces ‘bRCAness’ and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes,” Molecular Cancer Research, vol. 12, no. 11, pp. 1597–1609, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. M. D. Paraskevopoulou and A. G. Hatzigeorgiou, “Analyzing MiRNA-LncRNA interactions,” Methods in Molecular Biology, vol. 1402, pp. 271–286, 2016. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Bisso, M. Faleschini, F. Zampa et al., “Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer,” Cell Cycle, vol. 12, no. 11, pp. 1679–1687, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. P. Moskwa, F. M. Buffa, Y. Pan et al., “MiR-182-mediated downregulation of BRCA1 Impacts DNA repair and sensitivity to PARP inhibitors,” Molecular Cell, vol. 41, no. 2, pp. 210–220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Neijenhuis, I. Bajrami, R. Miller, C. J. Lord, and A. Ashworth, “Identification of miRNA modulators to PARP inhibitor response,” DNA Repair, vol. 12, no. 6, pp. 394–402, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. J.-W. Huang, Y. Wang, K. K. Dhillon et al., “Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity,” Molecular Cancer Research, vol. 11, no. 12, pp. 1564–1573, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Wang, J.-W. Huang, P. Calses, C. J. Kemp, and T. Taniguchi, “MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition,” Cancer Research, vol. 72, no. 16, pp. 4037–4046, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Lim, A. Janzer, A. Becker et al., “Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology,” Carcinogenesis, vol. 31, no. 3, pp. 512–520, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. N. Serce, A. Gnatzy, S. Steiner, H. Lorenzen, J. Kirfel, and R. Buettner, “Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast,” BMC Clinical Pathology, vol. 12, article 13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. N. Mosammaparast, H. Kim, B. Laurent et al., “The histone demethylase LSD1/KDM1A promotes the DNA damage response,” The Journal of Cell Biology, vol. 203, no. 3, pp. 457–470, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Nagasawa, A. S. Sedukhina, Y. Nakagawa et al., “LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition,” PLoS ONE, vol. 10, no. 2, Article ID e0118002, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. D. Blazek, J. Kohoutek, K. Bartholomeeusen et al., “The cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes,” Genes & Development, vol. 25, no. 20, pp. 2158–2172, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. D. Vrábel, M. Svoboda, J. Navrátil, and J. Kohoutek, “Function of CDK12 in tumor initiation and progression and its clinical consequences,” Klinicka Onkologie, vol. 27, no. 5, pp. 340–346, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. P. M. Joshi, S. L. Sutor, C. J. Huntoon, and L. M. Karnitz, “Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors,” The Journal of Biological Chemistry, vol. 289, no. 13, pp. 9247–9253, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. I. Bajrami, J. R. Frankum, A. Konde et al., “Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity,” Cancer Research, vol. 74, no. 1, pp. 287–297, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. I. Peset and I. Vernos, “The TACC proteins: TACC-ling microtubule dynamics and centrosome function,” Trends in Cell Biology, vol. 18, no. 8, pp. 379–388, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. P. Singh, G. E. Thomas, K. K. Gireesh, and T. K. Manna, “TACC3 protein regulates microtubule nucleation by affecting γ-tubulin ring complexes,” Journal of Biological Chemistry, vol. 289, no. 46, pp. 31719–31735, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. B. U. Nwagbara, A. E. Faris, E. A. Bearce et al., “TACC3 is a microtubule plus end-tracking protein that promotes axon elongation and also regulates microtubule plus end dynamics in multiple embryonic cell types,” Molecular Biology of the Cell, vol. 25, no. 21, pp. 3350–3362, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. I. H. Still, P. Vince, and J. K. Cowell, “The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines,” Genomics, vol. 58, no. 2, pp. 165–170, 1999. View at Publisher · View at Google Scholar · View at Scopus
  96. G.-H. Ha, J.-L. Kim, and E.-K. Y. Breuer, “TACC3 is essential for EGF-mediated EMT in cervical cancer,” PLoS ONE, vol. 8, no. 8, article e70353, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. G.-H. Ha, J.-L. Kim, A. Petersson et al., “TACC3 deregulates the DNA damage response and confers sensitivity to radiation and PARP inhibition,” Oncogene, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. T. Sourisseau, D. Maniotis, A. McCarthy et al., “Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition,” EMBO Molecular Medicine, vol. 2, no. 4, pp. 130–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Cazales, E. Schmitt, E. Montembault, C. Dozier, C. Prigent, and B. Ducommun, “CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage,” Cell Cycle, vol. 4, no. 9, pp. 1233–1238, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. Z. Wang, Y. Liu, L. Lu et al., “Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis,” Oncotarget, vol. 6, no. 9, pp. 6670–6683, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. J. M. Sun, L. N. Yang, H. Xu, B. Chang, H. Y. Wang, and G. Yang, “Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells,” American Journal of Cancer Research, vol. 5, no. 3, pp. 1133–1145, 2015. View at Google Scholar
  102. J. R. Bischoff, L. Anderson, Y. Zhu et al., “A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers,” EMBO Journal, vol. 17, no. 11, pp. 3052–3065, 1998. View at Publisher · View at Google Scholar · View at Scopus
  103. J.-L. Liu, Z. Mao, T. A. LaFortune et al., “Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade,” Cancer Research, vol. 67, no. 22, pp. 11054–11063, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. J. Olasz, Z. Doleschall, Z. Dunai, A. Pazsitka, and O. Csuka, “PI3K/AKT pathway activation and therapeutic consequences in breast cancer,” Magyar Onkologia, vol. 59, no. 4, pp. 346–351, 2015. View at Google Scholar
  105. V. Nodouzi, M. Nowroozi, M. Hashemi, G. Javadi, and R. Mahdian, “Concurrent down-regulation of PTEN and NKX3.1 expression in Iranian patients with prostate cancer,” The International Brazilian Journal of Urology, vol. 41, no. 5, pp. 898–905, 2015. View at Publisher · View at Google Scholar · View at Scopus
  106. W. H. Shen, A. S. Balajee, J. Wang et al., “Essential Role for Nuclear PTEN in maintaining chromosomal integrity,” Cell, vol. 128, no. 1, pp. 157–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  107. A. M. Mendes-Pereira, S. A. Martin, R. Brough et al., “Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors,” EMBO Molecular Medicine, vol. 1, no. 6-7, pp. 315–322, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. J.-S. Kim, C. Lee, C. L. Bonifant, H. Ressom, and T. Waldman, “Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA,” Molecular and Cellular Biology, vol. 27, no. 2, pp. 662–677, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Puc and R. Parsons, “PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells,” Cell Cycle, vol. 4, no. 7, pp. 927–929, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Fraser, H. Zhao, K. R. Luoto et al., “PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy,” Clinical Cancer Research, vol. 18, no. 4, pp. 1015–1027, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. C. R. Hunt, A. Gupta, N. Horikoshi, and T. K. Pandita, “Does PTEN loss impair DNA double-strand break repair by homologous recombination?” Clinical Cancer Research, vol. 18, no. 4, pp. 920–922, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. A. A. Arbini, F. Guerra, M. Greco et al., “Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2,” Oncogenesis, vol. 2, article e82, 2013. View at Publisher · View at Google Scholar · View at Scopus
  113. J. A. Watkins, S. Irshad, A. Grigoriadis, and A. N. J. Tutt, “Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers,” Breast Cancer Research, vol. 16, no. 3, article 211, 2014. View at Publisher · View at Google Scholar · View at Scopus
  114. S. Rottenberg, J. E. Jaspers, A. Kersbergen et al., “High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 44, pp. 17079–17084, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. T. Popova, E. Manié, G. Rieunier et al., “Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation,” Cancer Research, vol. 72, no. 21, pp. 5454–5462, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. J. B. Geigl, A. C. Obenauf, T. Schwarzbraun, and M. R. Speicher, “Defining 'chromosomal instability',” Trends in Genetics, vol. 24, no. 2, pp. 64–69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. H. Farmer, H. McCabe, C. J. Lord et al., “Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy,” Nature, vol. 434, no. 7035, pp. 917–921, 2005. View at Publisher · View at Google Scholar · View at Scopus
  118. I. Ibragimova and P. Cairns, “Assays for hypermethylation of the BRCA1 gene promoter in Tumor cells to predict sensitivity to PARP-Inhibitor therapy,” Methods in Molecular Biology, vol. 780, pp. 277–291, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. J. Veeck, S. Ropero, F. Setien et al., “BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors,” Journal of Clinical Oncology, vol. 28, no. 29, pp. e563–e566, 2010. View at Publisher · View at Google Scholar · View at Scopus
  120. M. Esteller, J. M. Silva, G. Dominguez et al., “Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors,” Journal of the National Cancer Institute, vol. 92, no. 7, pp. 564–569, 2000. View at Publisher · View at Google Scholar · View at Scopus
  121. Y. Drew, E. A. Mulligan, W.-T. Vong et al., “Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2,” Journal of the National Cancer Institute, vol. 103, no. 4, pp. 334–346, 2011. View at Publisher · View at Google Scholar · View at Scopus
  122. A. L. Bane, A. M. Mulligan, D. Pinnaduwage, F. P. O'Malley, and I. L. Andrulis, “EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry,” Breast Cancer Research and Treatment, vol. 127, no. 3, pp. 831–839, 2011. View at Publisher · View at Google Scholar · View at Scopus
  123. S. K. Pal and J. Mortimer, “Triple-negative breast cancer: novel therapies and new directions,” Maturitas, vol. 63, no. 4, pp. 269–274, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. N. C. Turner, C. J. Lord, E. Iorns et al., “A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor,” The EMBO Journal, vol. 27, no. 9, pp. 1368–1377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. M. W. Audeh, J. Carmichael, R. T. Penson et al., “Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial,” The Lancet, vol. 376, no. 9737, pp. 245–251, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. X. Wang and D. T. Weaver, “The ups and downs of DNA repair biomarkers for PARP inhibitor therapies,” American Journal of Cancer Research, vol. 1, no. 3, pp. 301–327, 2011. View at Google Scholar
  127. X. W. Meng, B. D. Koh, J.-S. Zhang et al., “Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression,” The Journal of Biological Chemistry, vol. 289, no. 30, pp. 20543–20558, 2014. View at Publisher · View at Google Scholar · View at Scopus
  128. M. I. Rodríguez, A. González-Flores, F. Dantzer, J. Collard, A. G. De Herreros, and F. J. Oliver, “Poly(ADP-ribose)-dependent regulation of Snail1 protein stability,” Oncogene, vol. 30, no. 42, pp. 4365–4372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  129. S.-W. Yu, S. A. Andrabi, H. Wang et al., “Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 48, pp. 18314–18319, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. M. I. Rodríguez, A. Peralta-Leal, F. O'Valle et al., “PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation,” PLoS Genetics, vol. 9, no. 6, article e1003531, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. N. Chan, I. M. Pires, Z. Bencokova et al., “Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment,” Cancer Research, vol. 70, no. 20, pp. 8045–8054, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. A. Pyriochou, G. Olah, E. A. Deitch, C. Szabó, and A. Papapetropoulos, “Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34,” International Journal of Molecular Medicine, vol. 22, no. 1, pp. 113–118, 2008. View at Google Scholar · View at Scopus
  133. L. Tentori, P. M. Lacal, A. Muzi et al., “Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis,” European Journal of Cancer, vol. 43, no. 14, pp. 2124–2133, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. M. Rajesh, P. Mukhopadhyay, S. Bátkai et al., “Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis,” Biochemical and Biophysical Research Communications, vol. 350, no. 2, pp. 352–357, 2006. View at Publisher · View at Google Scholar · View at Scopus
  135. N. Chan, M. Koritzinsky, H. Zhao et al., “Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance,” Cancer Research, vol. 68, no. 2, pp. 605–614, 2008. View at Publisher · View at Google Scholar · View at Scopus
  136. V. M. Neumeister, C. A. Sullivan, R. Lindner et al., “Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer,” Breast Cancer Research and Treatment, vol. 136, no. 1, pp. 67–75, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. K. R. Luoto, R. Kumareswaran, and R. G. Bristow, “Tumor hypoxia as a driving force in genetic instability,” Genome Integrity, vol. 4, article 5, 2013. View at Publisher · View at Google Scholar · View at Scopus
  138. S. J. Hill, A. P. Clark, D. P. Silver, and D. M. Livingston, “BRCA1 pathway function in basal-like breast cancer cells,” Molecular and Cellular Biology, vol. 34, no. 20, pp. 3828–3842, 2014. View at Publisher · View at Google Scholar · View at Scopus
  139. G. Illuzzi, E. Fouquerel, J.-C. Amé et al., “PARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress,” Nucleic Acids Research, vol. 42, no. 12, pp. 7776–7792, 2014. View at Publisher · View at Google Scholar · View at Scopus
  140. J. Luo, N. L. Solimini, and S. J. Elledge, “Principles of cancer therapy: oncogene and non-oncogene addiction,” Cell, vol. 136, no. 5, pp. 823–837, 2009. View at Publisher · View at Google Scholar · View at Scopus
  141. J. M. Stommel, A. C. Kimmelman, H. Ying et al., “Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies,” Science, vol. 318, no. 5848, pp. 287–290, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. V. Schreiber, F. Dantzer, J.-C. Amé, and G. de Murcia, “Poly(ADP-ribose): novel functions for an old molecule,” Nature Reviews Molecular Cell Biology, vol. 7, no. 7, pp. 517–528, 2006. View at Publisher · View at Google Scholar · View at Scopus
  143. C. E. Redon, A. J. Nakamura, Y.-W. Zhang et al., “Histone γH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers,” Clinical Cancer Research, vol. 16, no. 18, pp. 4532–4542, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. P. Gottipati, B. Vischioni, N. Schultz et al., “Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells,” Cancer Research, vol. 70, no. 13, pp. 5389–5398, 2010. View at Publisher · View at Google Scholar · View at Scopus
  145. L. Liu, W. Zhou, C.-T. Cheng et al., “TGFβ Induces ‘bRCAness’ and Sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes,” Molecular Cancer Research, vol. 12, no. 11, pp. 1597–1609, 2014. View at Publisher · View at Google Scholar · View at Scopus
  146. Y. Wang, Y. Yu, A. Tsuyada et al., “Transforming growth factor-Β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM,” Oncogene, vol. 30, no. 12, pp. 1470–1480, 2011. View at Publisher · View at Google Scholar · View at Scopus
  147. L. Hughes-Davies, D. Huntsman, M. Ruas et al., “EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer,” Cell, vol. 115, no. 5, pp. 523–535, 2003. View at Publisher · View at Google Scholar · View at Scopus
  148. I. Cousineau and A. Belmaaza, “EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases,” Molecular Genetics and Genomics, vol. 285, no. 4, pp. 325–340, 2011. View at Publisher · View at Google Scholar · View at Scopus
  149. P. M. Wilkerson, K. J. Dedes, D. Wetterskog et al., “Functional characterization of EMSY gene amplification in human cancers,” The Journal of Pathology, vol. 225, no. 1, pp. 29–42, 2011. View at Publisher · View at Google Scholar · View at Scopus
  150. S. M. Domchek, C. Aghajanian, R. Shapira-Frommer et al., “Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy,” Gynecologic Oncology, vol. 140, no. 2, pp. 199–203, 2016. View at Publisher · View at Google Scholar · View at Scopus
  151. J. Ledermann, P. Harter, C. Gourley et al., “Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial,” The Lancet Oncology, vol. 15, no. 8, pp. 852–861, 2014. View at Publisher · View at Google Scholar · View at Scopus
  152. BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People with Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment, May 2016, https://clinicaltrials.gov/ct2/show/NCT02326844?term=talazoparib&rank=9.
  153. A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients with BRCA Mutation (EMBRACA Study), (EMBRACA), May 2016, https://clinicaltrials.gov/ct2/show/NCT01945775?term=talazoparib&rank=8.
  154. Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients with Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors, October 2015, https://clinicaltrials.gov/ct2/show/NCT01326702?term=veliparib&rank=10.
  155. Veliparib and Topotecan for Relapsed Ovarian Cancer with Negative or Unknown BRCA Status, June 2015, https://clinicaltrials.gov/ct2/show/NCT01690598?term=veliparib&rank=22.
  156. Gemcitabine Hydrochloride and Cisplatin with or Without Veliparib or Veliparib Alone in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer, June 2016, https://clinicaltrials.gov/ct2/show/NCT01585805?term=nct01585805&rank=1.
  157. A Study of Rucaparib in Patients with Pancreatic Cancer and a Known Deleterious BRCA Mutation, December 2015, https://clinicaltrials.gov/ct2/show/NCT02042378?term=rucaparib&rank=1.
  158. A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3), April 2016, https://clinicaltrials.gov/ct2/show/NCT01968213?term=rucaparib&rank=3.
  159. ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients with Previously Treated, Incurable Ewing Sarcoma, May 2016, https://clinicaltrials.gov/ct2/show/NCT02044120?term=niraparib&rank=7.
  160. “A phase III trial of niraparib versus physician's choice in HER2 negative, germline BRCA mutation-positive breast cancer patients (BRAVO),” https://clinicaltrials.gov/ct2/show/NCT01905592?term=niraparib&rank=6.
  161. A Study of Niraparib in Patients with Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens, January 2016, https://clinicaltrials.gov/ct2/show/NCT02354586?term=niraparib&rank=5.